Is intravenous cefepime appropriate for treating a Klebsiella urinary tract infection in a hospitalized adult, and what dosing regimen should be used based on renal function?

IV Cefepime for Klebsiella Urinary Tract Infection

IV cefepime is an appropriate and effective treatment for Klebsiella urinary tract infections in hospitalized adults, with dosing of 1-2 g IV every 12 hours for uncomplicated/complicated UTI or 2 g IV every 12 hours for severe infections, adjusted for renal function. 1, 2

Clinical Appropriateness

Cefepime is explicitly recommended by the 2024 European Association of Urology guidelines as a parenteral antimicrobial for uncomplicated pyelonephritis requiring hospitalization 1. The guidelines list cefepime at 1-2 g twice daily as an appropriate empirical choice for hospitalized patients, noting that the lower dose has been studied but the higher dose is recommended 1.

For Klebsiella specifically, cefepime provides excellent coverage as an extended-spectrum cephalosporin with activity against common uropathogens including Klebsiella pneumoniae 2. The FDA label confirms approval for both uncomplicated and complicated UTIs including pyelonephritis caused by K. pneumoniae 2.

Dosing Regimen Based on Severity

Mild to Moderate UTI

• 0.5-1 g IV every 12 hours for 7-10 days 2
• This applies to uncomplicated or complicated UTI without severe illness

Severe UTI

• 2 g IV every 12 hours for 10 days 2
• Use this dose for severe uncomplicated or complicated UTI due to E. coli or K. pneumoniae

Infusion Details

• Administer intravenously over approximately 30 minutes 2
• Can be given via intermittent IV infusion with Y-type administration set 2

Renal Function Adjustments

Critical caveat: Dosing must be adjusted for creatinine clearance ≤60 mL/min to prevent neurotoxicity 2. This is particularly important in geriatric patients where serious adverse reactions have occurred with unadjusted doses 2.

Adjustment Algorithm:

• CrCl >60 mL/min: Standard dosing as above
• CrCl 30-60 mL/min:
  • Mild-moderate: 500 mg every 24 hours
  • Severe: 2 g every 12 hours
• CrCl 11-29 mL/min:
  • Mild-moderate: 500 mg every 24 hours
  • Severe: 1 g every 24 hours
• CrCl <11 mL/min:
  • Mild-moderate: 250 mg every 24 hours
  • Severe: 500 mg every 24 hours
• Hemodialysis: 1 g on day 1, then 500 mg every 24 hours (give after dialysis) 2

Resistance Considerations

While cefepime is appropriate for susceptible Klebsiella, always obtain culture and susceptibility testing before initiating therapy 1, 3. If the isolate proves to be carbapenem-resistant Enterobacterales (CRE), cefepime is inadequate and newer agents are required:

• Ceftazidime-avibactam 2.5 g IV every 8 hours 4
• Meropenem-vaborbactam 4 g IV every 8 hours 4
• Imipenem-cilastatin-relebactam 1.25 g IV every 6 hours 4

These agents should be reserved for confirmed multidrug-resistant organisms based on antibiotic stewardship principles 4, 1.

Clinical Efficacy Data

Historical data demonstrates cefepime 1 g twice daily achieved 94% clinical cure rate and 93% pathogen eradication for bacterial UTIs including those caused by K. pneumoniae 5. In severe UTI, clinical and bacteriological efficacy reached 93.2% and 85.4% respectively with 1-2 g daily dosing 6.

Key Pitfalls to Avoid

1. Failure to adjust for renal impairment: This is the most common error leading to neurotoxicity, especially in elderly patients 2, 7

2. Underdosing in augmented renal clearance: Patients with CrCl >100 mL/min may have subtherapeutic levels with standard dosing, particularly for pathogens with MIC ≥4 mg/L 7

3. Using cefepime for ESBL or CRE: If susceptibility testing reveals extended-spectrum beta-lactamase production or carbapenem resistance, switch to appropriate agents 4

4. Inadequate infusion time: Prolonged infusion may be beneficial for pathogens with higher MICs, though standard 30-minute infusion is typically adequate 4